World Health Organization (WHO)
Chairs: Jessica Shi & Kaylyn Lu
Topic A: Infant Mortality Rate
In countries all over the world, 2.1 is the typical rate for Replacement-level fertility, a term branched from the umbrella term of Total Fertility Rate (TFR). 2.1 in simpler terms signifies a constant population, whereas a number lower than 2.1 would indicate a decreasing population and a number higher than 2.1 would indicate an increasing population. Each country in the world contains a different TFR, and is often correlated with the level of development each country is associated under. Especially in developing countries, the infant mortality rate has increased due to lack of prevalent prenatal care or basic healthcare. The World Health Organization has been avidly attempting to palliate the percentages of infant mortalities that have been occurring: statistically, 800 females die each day from pregnancy or birth issues and each hour roughly around 900 children aged due to a lack of developmental resources worldwide. This committee will focus on identifying potential issues that may serve as a barrier to decreasing the infant mortality rate worldwide and strengthen existing services and programs that work well toward the WHO’s goal.
Topic B: Access to Medicine in Developing Countries
Developing countries face various barriers in obtaining medicine and basic health care that developed countries do not prioritize worrying about. The socio-economic north and south divide classify countries in the world as developing and developed. Target 8e of the UN’s Millennium Development Goals (MDGs) aims to “provide access to affordable essential drugs in developing countries (through cooperation with pharmaceutical companies)”. In comparison to other targets of Goal 8, access to medicine in developing countries is still extremely lacking in terms of progress made. In order to improve access to medicine, these products must be sufficiently available and affordable to the general public. According to research conducted by the MDG Gap Task Force, the prices of generic medicines for patients in low and lower-middle income countries maintain an extremely high price, with an average of three times more expensive than international reference prices. People in these countries are in critical need of legislative solutions as well as the collaboration of pharmaceutical companies around the world. This committee will focus on creating resolutions to aid developing countries in reaching a higher standard for medicinal access.